Core Viewpoint - Jinxin Fertility Group experienced a significant decline in stock price, reflecting challenges in its financial performance and market position [1][2]. Company Overview - Jinxin Fertility Group is a leading assisted reproductive services provider in China and the U.S., operating multiple hospitals and medical centers [1]. - The company ranked third in the Chinese assisted reproductive services market in 2018, conducting 20,958 in vitro fertilization cycles, with a market share of approximately 3.1%, and ranked first among non-state-owned institutions [1]. Financial Performance - For the mid-year report of 2025, Jinxin Fertility reported total revenue of 1.289 billion RMB and a net profit of -1.04 billion RMB [2]. - The company's profit attributable to shareholders for the fiscal year 2025 decreased by 648.24% year-on-year, resulting in a basic earnings per share of -0.39 RMB [2].
锦欣生殖(01951)下跌5.07%，报3.18元/股